Novartis AG (NVS) Q3 2026 Earnings Call Transcript

Novartis AG ( NVS ) Q3 2026 Earnings Call October 27, 2026 8:00 AM EDT Company Participants Isabella Zinck - Investor Relations Manager Vasant Narasimhan - Chief Executive Officer Mukul Mehta - Chief Financial Officer Conference Call Participants Sachin Jain - BofA Securities, Research Division James Gordon - Barclays Bank PLC, Research Division Florent Cespedes - ODDO BHF Corporate & Markets, Research Division Graham Glyn Parry - Citigroup Inc., Research Division Kerry Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Steve Scala - TD Cowen, Research Division James Quigley - Goldman Sachs Group, Inc., Research Division Trung Huynh - RBC Capital Markets, Research Division Thibault Boutherin - Morgan Stanley, Research Division Matthew Weston - UBS Investment Bank, Research Division Peter Verdult - BNP Paribas, Research Division Michael Leuchten - Jefferies LLC, Research Division Richard Vosser - JPMorgan Chase & Co, Research Division Urban Fritsche - Zürcher Kantonalbank, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Presentation Isabella Zinck Investor Relations Manager Hi, everyone, and welcome to our Q3 earnings call.

Seeking Alpha • 9 hours ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Investment Research • Oct 28, 2026

Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit

Novartis AG (NYSE:NVS) reported mixed third-quarter earnings on Tuesday as the prized Avidity Biosciences deal worth $12 billion cost the company an estimated $1.9 billion in impairment charges, primarily driven by the timeline shifting due to additional clinical work to be completed.

Benzinga • Oct 27, 2026

Novartis Hikes Income Forecast, But There Were Caveats Within Its Report

Novartis stock rose slightly early Tuesday on strong third-quarter income, but the company's biggest moneymaker, Kisqali, fell short.

Investors Business Daily • Oct 27, 2026

What Novartis (NVS) Said on Its Q3 Earnings Call

Novartis NYSE: NVS reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core operating income.

MarketBeat • Oct 27, 2026

Novartis Raises Guidance Despite Trial Setbacks Hitting Profit

The Swiss drugmaker cited solid sales growth and productivity gains, even as recent clinical-trial setbacks hit its bottom line in the third quarter.

WSJ • Oct 27, 2026

Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research • Oct 27, 2026

NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss

Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.

Zacks Investment Research • Oct 27, 2026

4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential

LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.

Zacks Investment Research • Oct 27, 2026

Novartis raises full year core operating income guidance

Novartis raised its ​full-year core operating ‌income guidance on Tuesday after ​strong third-quarter ​demand for its ⁠key cancer ​and multiple sclerosis ​drugs.

Reuters • Oct 27, 2026